Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DLI or second transplant.

H T Greinix1

  • 1Department of Medicine I, Bone Marrow Transplantation, University of Vienna, Austria.

Annals of Hematology
|March 4, 2003
PubMed
Summary

Second allogeneic hematopoietic stem cell transplantation (HSCT) and donor lymphocyte infusions (DLI) offer survival benefits for patients with relapsed hematologic malignancies. Further research is needed to optimize outcomes for these challenging cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation.

Leukemia·2017
Same author

The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation.

Leukemia·2016
Same author

Secondary solid cancer screening following hematopoietic cell transplantation.

Bone marrow transplantation·2015
Same author

Personality influences quality-of-life assessments in adult patients after allogeneic hematopoietic SCT: results from a joint evaluation of the prospective German Multicenter Validation Trial and the Fred Hutchinson Cancer Research Center.

Bone marrow transplantation·2012
Same author

Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients.

Journal of internal medicine·2012
Same author

Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study.

Leukemia·2011

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Relapse after initial hematopoietic stem cell transplantation (HSCT) presents a significant challenge in managing hematologic malignancies and some solid tumors.
  • Limited therapeutic options exist for patients who relapse post-HSCT, necessitating evaluation of salvage strategies.

Purpose of the Study:

  • To evaluate the toxicity and efficacy of second allogeneic HSCT and donor lymphocyte infusions (DLI) in patients with relapsed hematologic malignancies and metastatic renal cell carcinoma.
  • To identify factors influencing outcomes in patients undergoing these salvage therapies.

Main Methods:

  • Retrospective analysis of 66 patients with relapsed malignancies who received either a second HSCT (n=41) or DLI (n=25).
  • Patient cohorts included acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, myeloma, myelodysplastic syndrome, and metastatic renal cell carcinoma.
  • Outcomes assessed included survival, disease-free survival, and treatment-related toxicity.

Main Results:

  • Sixteen patients (39%) achieved disease-free survival after a second HSCT, with a notable success rate (13/16) in those receiving nonmyeloablative conditioning.
  • Thirteen patients (52%) remained alive after DLI, predominantly chronic myeloid leukemia patients in continuous complete remission.
  • Overall survival rates indicate potential benefit from both second HSCT and DLI, though patient selection and disease type appear influential.

Conclusions:

  • Second HSCT and DLI can be effective salvage strategies for patients relapsing after initial HSCT, offering a chance for long-term disease control.
  • Nonmyeloablative conditioning may improve outcomes for patients undergoing a second HSCT.
  • Further investigation is warranted to refine patient selection and treatment protocols to enhance the success rates of these advanced therapies.

Related Experiment Videos